List of Publications by Year in descending order

212 papers	16,888 citations	15495 65 h-index	16164 124 g-index
216 all docs	216 docs citations	216 times ranked	9437 citing authors

#	Article	IF	Citations
1	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology, 1993, 105, 229-236.	0.6	820
2	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology, 2003, 38, 258-266.	3.6	744
3	Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology, 1988, 94, 1493-1502.	0.6	599
4	Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology, 2005, 42, 439-447.	3.6	537
5	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	3.6	497
6	Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Gastroenterology, 1987, 93, 234-241.	0.6	463
7	Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology, 1988, 94, 482-487.	0.6	438
8	Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2003, 38, 1210-1218.	3.6	430
9	Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality. Hepatology, 1998, 27, 1227-1232.	3.6	387
10	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology, 2000, 33, 43-48.	1.8	381
11	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology, 1998, 28, 416-422.	3.6	374
12	MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology, 2005, 41, 1282-1289.	3.6	338
13	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology, 2003, 125, 117-125.	0.6	317
14	Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27, 35-41.	3.6	296
15	Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. Cell, 2010, 141, 178-190.	13.5	243
16	Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology, 1998, 28, 851-864.	3.6	237
17	Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology, 2007, 46, 1919-1926.	3.6	236
18	A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology, 2005, 42, 627-634.	3.6	229

#	Article	IF	Citations
19	A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology, 2001, 34, 46-52.	1.8	225
20	Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology, 2002, 122, 85-93.	0.6	222
21	Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology, 1990, 98, 146-151.	0.6	208
22	Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. Hepatology, 1992, 15, 343-349.	3.6	201
23	Circulating levels of endothelin in cirrhosis. Gastroenterology, 1993, 104, 1485-1491.	0.6	198
24	Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. Journal of Hepatology, 2012, 57, 267-273.	1.8	191
25	Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology, 1993, 17, 355-360.	3.6	183
26	Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology, 1990, 99, 1736-1744.	0.6	179
27	Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. Journal of Hepatology, 2016, 64, 691-698.	1.8	178
28	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 1988, 8, 636-642.	3.6	170
29	Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 475-483.	1.3	150
30	ARFI, FibroScanÂ®, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. Journal of Hepatology, 2012, 57, 281-287.	1.8	150
31	Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. Hepatology, 1993, 18, 367-372.	3.6	142
32	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. Journal of Hepatology, 2004, 41, 384-390.	1.8	141
33	Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology, 1998, 28, 39-44.	3.6	138
34	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. Hepatology, 1993, 17, 788-793.	3.6	136
35	Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method. Hepatology, 1985, 5, 815-818.	3.6	125
36	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. Hepatology, 1994, 20, 839-844.	3.6	124

#	Article	IF	Citations
37	Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology, 2003, 125, 522-531.	0.6	121
38	Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology, 1985, 5, 245-250.	3.6	117
39	Neutrophil Gelatinaseâ€Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70, 319-333.	3.6	114
40	The hepatic apelin system: A new therapeutic target for liver disease. Hepatology, 2008, 48, 1193-1201.	3.6	113
41	Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology, 1998, 114, 336-343.	0.6	103
42	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Scientific Reports, 2016, 6, 32341.	1.6	101
43	Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. Journal of Hepatology, 2014, 61, 35-42.	1.8	98
44	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. PLoS ONE, 2015, 10, e0128145.	1.1	97
45	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology, 2014, 147, 628-636.e1.	0.6	94
46	Gene Expression of Endothelin-1 and ET_A and ET_B Receptors in Human Cirrhosis: Relationship with Hepatic Hemodynamics. Journal of Vascular Research, 1998, 35, 186-193.	0.6	92
47	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology, 1995, 22, 753-758.	3.6	90
48	Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology, 1995, 21, 554-560.	3.6	88
49	Increased nitric oxideâ€"dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology, 1994, 20, 1615-1621.	3.6	86
50	Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites. Seminars in Liver Disease, 1994, 14, 44-58.	1.8	85
51	Cerium Oxide Nanoparticles: Advances in Biodistribution, Toxicity, and Preclinical Exploration. Small, 2020, 16, e1907322.	5.2	85
52	Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo. Journal of Hepatology, 1997, 26, 614-620.	1.8	84
53	Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects. Gastroenterology, 1999, 116, 161-167.	0.6	83
54	Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. Journal of Hepatology, 1994, 20, 282-288.	1.8	80

#	Article	IF	Citations
55	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology, 2005, 41, 579-587.	3.6	79
56	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology, 1991, 100, 494-501.	0.6	78
57	Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. Kidney International, 2000, 58, 216-228.	2.6	75
58	Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertility and Sterility, 1991, 56, 1077-1083.	0.5	73
59	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology, 2003, 38, 452-459.	3.6	73
60	Carbon tetrachloride induced cirrhosis in rats: A useful tool for investigating the pathogenesis of ascites in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 90-97.	1.4	70
61	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology, 2000, 119, 794-805.	0.6	69
62	Nitric Oxide Synthase 3-Dependent Vascular Remodeling and Circulatory Dysfunction in Cirrhosis. American Journal of Pathology, 2003, 162, 1985-1993.	1.9	69
63	Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H550-H555.	1.5	69
64	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology, 1999, 29, 1057-1063.	3.6	68
65	Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation. Gastroenterology, 2010, 138, 147-158.e1.	0.6	68
66	Inhibition of 5â€lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB Journal, 2003, 17, 1745-1747.	0.2	67
67	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology, 1995, 22, 915-920.	3.6	65
68	Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. Journal of Hepatology, 1998, 28, 639-645.	1.8	64
69	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International, 2019, 39, 1246-1255.	1.9	64
70	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology, 1989, 97, 1294-1299.	0.6	63
71	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology, 1999, 116, 1167-1175.	0.6	61
72	Effects of contrast media on renal function in patients with cirrhosis: A prospective study. Hepatology, 2004, 40, 646-651.	3.6	61

#	Article	IF	Citations
73	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology, 1994, 20, 948-954.	3.6	60
74	Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut, 2011, 60, 1404-1411.	6.1	60
75	Assessment of the renin-angiotensin system in cirrhotic patients. Journal of Hepatology, 1992, 15, 179-183.	1.8	59
76	Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology, 1995, 108, 1842-1848.	0.6	59
77	Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. Journal of Hepatology, 1997, 27, 645-653.	1.8	59
78	Apelin Mediates the Induction of Profibrogenic Genes in Human Hepatic Stellate Cells. Endocrinology, 2010, 151, 5306-5314.	1.4	58
79	Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. Journal of Hepatology, 1996, 25, 916-923.	1.8	57
80	Prevention of Fibrosis Progression in CCl₄-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 629-637.	1.3	56
81	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology, 1994, 20, 30-33.	3.6	55
82	Aktâ€mediated foxo1 inhibition is required for liver regeneration. Hepatology, 2016, 63, 1660-1674.	3.6	55
83	Effects of somatostatin on renal function in cirrhosis. Gastroenterology, 1992, 103, 1868-1874.	0.6	54
84	Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosisâ€”a serological evaluation. Liver International, 2013, 33, 439-447.	1.9	50
85	Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. Journal of Hepatology, 1995, 22, 389-398.	1.8	49
86	Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. Hepatology, 2006, 44, 1555-1563.	3.6	49
87	PCA3 in the detection and management of early prostate cancer. Tumor Biology, 2013, 34, 1337-1347.	0.8	48
88	Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut, 2013, 62, 138-145.	6.1	47
89	Intrinsic and Extrinsic Properties Affecting Innate Immune Responses to Nanoparticles: The Case of Cerium Oxide. Frontiers in Immunology, 2017, 8, 970.	2.2	45
90	Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Gastroenterology, 1992, 102, 280-286.	0.6	44

#	Article	IF	Citations
91	Aquaretic effect of the Î¹-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology, 1995, 109, 217-223.	0.6	44
92	High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. Journal of Hepatology, 2004, 40, 424-430.	1.8	44
93	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. British Journal of Pharmacology, 2002, 135, 891-900.	2.7	43
94	Increased Expression of the Reninâ€“Angiotensin System and Mast Cell Density But Not of Angiotensin-converting Enzyme II in Late Stages of Human Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 1117-1125.	0.3	43
95	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology, 1995, 22, 479-487.	3.6	41
96	Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology, 1999, 30, 670-676.	3.6	41
97	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. Gastroenterology, 2007, 133, 2019-2028.	0.6	41
98	Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. Antioxidants, 2021, 10, 660.	2.2	41
99	Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachlorideâ€“induced cirrhosis. Hepatology, 1991, 13, 585-589.	3.6	40
100	Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension. Kidney International, 2000, 57, 664-670.	2.6	40
101	Microarray Analysis of Endothelial Differentially Expressed Genes in Liver of Cirrhotic Rats. Gastroenterology, 2005, 129, 1686-1695.	0.6	40
102	Grapheneâ€“Dendrimer Nanostars for Targeted Macrophage Overexpression of Metalloproteinase 9 and Hepatic Fibrosis Precision Therapy. Nano Letters, 2018, 18, 5839-5845.	4.5	40
103	Ascites and Liver Test Abnormalities During Severe Ovarian Hyperstimulation Syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.2	39
104	Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. Journal of Hepatology, 1998, 29, 789-795.	1.8	38
105	Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. Journal of Hepatology, 2003, 38, 755-761.	1.8	38
106	Cerium oxide nanoparticles improve liver regeneration after acetaminophen-induced liver injury and partial hepatectomy in rats. Journal of Nanobiotechnology, 2019, 17, 112.	4.2	38
107	Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2001, 34, 487-493.	3.6	37
108	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. Hepatology, 2020, 72, 1267-1282.	3.6	37

#	Article	IF	Citations
109	Effect of Demeclocycline on Renal Function and Urinary Prostaglandin E₂ and Kallikrein in Hyponatremic Cirrhotics. Nephron, 1984, 36, 30-37.	0.9	36
110	Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. Journal of Hepatology, 1996, 24, 506-512.	1.8	35
111	Effect of bacterial lipopolysaccharide on endothelin-1 production in human vascular endothelial cells. Journal of Hepatology, 1997, 26, 81-87.	1.8	35
112	Circulatory Dysfunction in Asymptomaticin VitroFertilization Patients. Relationship with Hyperestrogenemia and Activity of Endogenous Vasodilators1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1489-1493.	1.8	35
113	Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology, 2002, 36, 1172-1179.	3.6	35
114	The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver International, 2005, 25, 429-437.	1.9	35
115	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 914-920.	1.8	35
116	Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. Scientific Reports, 2019, 9, 12848.	1.6	35
117	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARÎ³. Influence of albumin. Journal of Hepatology, 2005, 42, 75-81.	1.8	34
118	Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules, 2019, 9, 425.	1.8	34
119	Effect of Dipyridamole on Kidney Function in Cirrhosis. Hepatology, 1993, 17, 59-64.	3.6	33
120	Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertility and Sterility, 2002, 78, 1261-1267.	0.5	31
121	Overexpression of angiopoietinâ€2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392.	1.9	31
122	Role of altered systemic hemodynamics in the blunted renal response to atrial natriuretic peptide in rats with cirrhosis and ascites. Journal of Hepatology, 1989, 9, 217-226.	1.8	29
123	Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney International, 2005, 67, 622-630.	2.6	29
124	Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clinical Chemistry and Laboratory Medicine, 2016, 54, 125-32.	1.4	29
125	The Role of Akt in Chronic Liver Disease and Liver Regeneration. Seminars in Liver Disease, 2017, 37, 011-016.	1.8	29
126	Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis and Tissue Repair, 2011, 4, 19.	3.4	28

#	Article	IF	Citations
127	Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes. International Journal of Molecular Sciences, 2019, 20, 5959.	1.8	28
128	Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. Cells, 2019, 8, 1311.	1.8	27
129	Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. Kidney International, 1991, 40, 182-187.	2.6	25
130	Plasma endothelin-1 and clinical manifestations of neonatal sepsis. Journal of Perinatal Medicine, 2004, 32, 522-6.	0.6	25
131	Treatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia. ACS Nano, 2021, 15, 7547-7562.	7.3	25
132	Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 662-667.	1.3	24
133	Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. Journal of Hepatology, 2001, 34, 222-229.	1.8	24
134	Microwave-assisted derivatization: Application to steroid profiling by gas chromatography/mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 8-13.	1.2	24
135	Increased plasma levels of neuropeptide Y in hepatorenal syndrome. Journal of Hepatology, 2002, 36, 349-355.	1.8	23
136	Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. World Journal of Gastroenterology, 2017, 23, 3163.	1.4	23
137	Rapid Increase in Plasma Levels of Atrial Natriuretic Peptide After Common Bile Duct Ligation in the Rabbit. Annals of Surgery, 1992, 216, 554-559.	2.1	22
138	Endocannabinoids and liver disease. Hepatology, 2005, 41, 983-985.	3.6	22
139	Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis. Gastroenterology, 1994, 107, 1201-1203.	0.6	21
140	Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Human Reproduction, 2007, 22, 669-675.	0.4	21
141	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. Journal of Hepatology, 2022, 76, 107-114.	1.8	21
142	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. PLoS ONE, 2016, 11, e0157371.	1.1	20
143	Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrhosis. Hepatology, 1990, 11, 379-386.	3.6	19
144	Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology, 1990, 12, 467-475.	3.6	19

#	Article	IF	Citations
145	Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis. Journal of Hepatology, 1994, 21, 521-526.	1.8	19
146	Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. International Journal of Cardiology, 2016, 223, 458-464.	0.8	19
147	Increased renal expression of nitric oxide synthase type III in cirrhotic rats with ascites. Hepatology, 1998, 27, 1191-1199.	3.6	18
148	Regulation of cyclooxygenase-2 expression in human mesangial cells - transcriptional inhibition by IL-13. FEBS Journal, 1999, 260, 268-274.	0.2	18
149	Increased activity of guanosine 3â€²-5â€²-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology, 2000, 31, 304-310.	3.6	18
150	Adrenomedullin and vascular endothelial growth factor production by follicular fluid macrophages and granulosa cells. Human Reproduction, 2004, 19, 808-814.	0.4	18
151	Impaired liver regeneration in Ldlrâ^'/â^' mice is associated with an altered hepatic profile of cytokines, growth factors, and lipids. Journal of Hepatology, 2013, 59, 731-737.	1.8	18
152	Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. Hepatology, 2016, 63, 207-216.	3.6	18
153	Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. Hepatology, 1991, 14, 601-607.	3.6	17
154	Immunoreactive endothelin plasma levels in severe ovarian hyperstimulation syndrome. Fertility and Sterility, 1995, 64, 65-68.	0.5	17
155	LH/HCG stimulation of VEGF and adrenomedullin production by follicular fluid macrophages and luteinized granulosa cells. Reproductive BioMedicine Online, 2009, 18, 743-749.	1.1	17
156	Impaired extracellular matrix degradation in aortic vessels of cirrhotic rats. Journal of Hepatology, 2007, 46, 440-446.	1.8	16
157	Follow-Up After Myocardial Infarction toÂExplore the Stability of Arrhythmogenic Substrate. JACC: Clinical Electrophysiology, 2020, 6, 207-218.	1.3	16
158	Urinary endothelin-like immunoreactivity in patients with cirrhosis. Journal of Hepatology, 1997, 27, 810-816.	1.8	15
159	Sustained aquaretic effect of the V2 -AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. British Journal of Pharmacology, 2005, 146, 654-661.	2.7	15
160	Impaired responsiveness to angiotensin II in experimental cirrhosis. Hepatology, 1994, 20, 266-268.	3.6	14
161	Chronology of hemodynamic changes in asymptomatic in vitro fertilization patients and relationship with ovarian steroids and cytokines. Fertility and Sterility, 2002, 77, 1178-1183.	0.5	14
162	A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. Journal of Hepatology, 2005, 43, 92-97.	1.8	14

#	Article	IF	Citations
163	Adrenomedullin and nitric oxide in menstrual and in vitro fertilization cycles. Relationship to estradiol. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 626-631.	1.3	13
164	Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. Journal of Hepatology, 2005, 43, 85-91.	1.8	13
165	Factors Involved in Extracellular Matrix Turnover in Human Derived Cardiomyocytes. Cellular Physiology and Biochemistry, 2013, 32, 1125-1136.	1.1	13
166	Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta, 2014, 435, 53-58.	0.5	13
167	Prognostic value of plasma apelin concentrations at admission in patients with ST-segment elevation acute myocardial infarction. Clinical Biochemistry, 2017, 50, 279-284.	0.8	13
168	Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats. PLoS ONE, 2019, 14, e0218716.	1.1	13
169	Neovascularization, Angiogenesis, and Vascular Remodeling in Portal Hypertension. , 2005, , 99-112.		13
170	Lack of a 5.9 kDa Peptide C-Terminal Fragment of Fibrinogen Î± Chain Precedes Fibrosis Progression in Patients with Liver Disease. PLoS ONE, 2014, 9, e109254.	1.1	12
171	Mesoporous silica coated CeO2 nanozymes with combined lipid-lowering and antioxidant activity induce long-term improvement of the metabolic profile in obese Zucker rats. Nanoscale, 2021, 13, 8452-8466.	2.8	12
172	Pathogenesis of sodium retention in cirrhosis. Journal of Hepatology, 1993, 18, 147-150.	1.8	11
173	Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.2	11
174	Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segment elevation myocardial infarction. Heart Rhythm, 2017, 14, 592-598.	0.3	11
175	Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 28-34.	1.2	11
176	An evaluation of the SENTiFIT 270 analyser for quantitation of faecal haemoglobin in the investigation of patients with suspected colorectal cancer. Clinical Chemistry and Laboratory Medicine, 2018, 56, 625-633.	1.4	11
177	Tetrahydrobiopterin Modulates Cyclooxygenase-2 Expression in Human Mesangial Cells. Biochemical and Biophysical Research Communications, 1997, 241, 7-12.	1.0	9
178	Bacterial lipopolyshaccaride inhibits CB2 receptor expression in human monocytic cells. Gut, 2013, 62, 1089-1091.	6.1	9
179	Scalable synthesis of multicomponent multifunctional inorganic core@mesoporous silica shell nanocomposites. Materials Science and Engineering C, 2021, 128, 112272.	3.8	9
180	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	3.6	8

#	Article	IF	Citations
181	Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology, 2003, 37, 13-15.	3.6	8
182	Pathophysiology of Portal Hypertension. , 2015, , 3631-3665.		8
183	Circulating levels of nitric oxide in successful and unsuccessful implantation after in vitro fertilization and embryo transfer. Relationship to estradiol and progesterone. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 564-569.	1.3	7
184	Validation of a Gas Chromatography-Mass Spectrometry Method for the Measurement of the Redox State Metabolic Ratios Lactate/Pyruvate and Î²-Hydroxybutyrate/Acetoacetate in Biological Samples. International Journal of Molecular Sciences, 2021, 22, 4752.	1.8	7
185	Adrenomedullin and nitric oxide in menstrual and in vitro fertilization cycles. Relationship to estradiol. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 626-631.	1.3	6
186	Monocyte Subsets Are Differently Associated with Infarct Size, Left Ventricular Function, and the Formation of a Potentially Arrhythmogenic Scar in Patients with Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2020, 13, 722-730.	1.1	5
187	The loss of DHX15 impairs endothelial energy metabolism, lymphatic drainage and tumor metastasis in mice. Communications Biology, 2021, 4, 1192.	2.0	5
188	The pituitary tumourâ€transforming gene 1/deltaâ€like homologue 1 pathway plays a key role in liver fibrogenesis. Liver International, 2022, 42, 651-662.	1.9	5
189	Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases. International Journal of Molecular Sciences, 2022, 23, 6897.	1.8	5
190	Platelet cytosolic calcium concentration in patients with liver cirrhosis. Journal of Hepatology, 1997, 27, 824-829.	1.8	4
191	Circulating levels of nitric oxide in successful and unsuccessful implantation after in vitro fertilization and embryo transfer. Relationship to estradiol and progesterone. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 564-569.	1.3	4
192	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. Comparative Hepatology, 2004, 3, S19.	0.9	4
193	Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats. Biology Open, 2016, 5, 858-865.	0.6	4
194	Acetylcholine-induced vasorelaxation in portal hypertensive rats. Hepatology, 1995, 22, 1009-1011.	3.6	2
195	Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases. Translational Oncology, 2016, 9, 445-452.	1.7	2
196	Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases. Future Oncology, 2017, 13, 875-882.	1.1	2
197	Fibrinogen Î±-Chain as a Serum Marker of Liver Disease. Biomarkers in Disease, 2017, , 493-511.	0.0	2
198	Blunted natriuretic response to human urine extracts with Na+, K+-ATPase inhibiting activity in experimental cirrhosis. Journal of Hepatology, 1994, 20, 660-665.	1.8	1

#	Article	IF	Citations
199	Insulin therapy in type 2 diabetic patients: effects on arterial blood pressure and endothelin-1 plasma levels. Diabetes Research and Clinical Practice, 1998, 41, 151-155.	1.1	1
200	FRI-334-Cerium oxide nanoparticles present antilipogenic and antiinflammatory effects in rats with diet-induced non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 70, e543.	1.8	1
201	Catalytic Cerium Oxide Nanoparticles in Nanomedicine and Their Use in Liver Diseases. , 2019, , .		1
202	Nitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis. , 0, , 105-114.		1
203	Pathophysiology of Portal Hypertension. , 2014, , 1-41.		1
204	Hepatorenal Syndrome and Other Liver-Related Kidney Diseases. , 2014, , 268-276.		0
205	Letter in reply: Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases. Future Oncology, 2017, 13, 1135-1136.	1.1	0
206	Renal Effects of Selective Cyclooxygenase Inhibition in Experimental Liver Disease. Advances in Experimental Medicine and Biology, 2003, 525, 133-136.	0.8	0
207	Endogenous cannabinoids and circulatory dysfunction in cirrhosis. , 2004, , 97-101.		0
208	Renal Function in Liver Disease. , 2009, , 261-267.		0
209	Angiogenesis and Vascular Growth in Liver Diseases. , 2011, , 343-359.		0
210	Fibrinogen Î±-Chain as a Serum Marker of Liver Disease. Exposure and Health, 2015, , 1-20.	2.8	0
211	Biopsia lÃquida: un reto para el laboratorio de diagnÃ³stico clÃnico. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
212	Liquid biopsy. A challenge for clinical laboratories. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0